Rationale: Acute-on-chronic liver failure (ACLF) is a life-threatening acute deterioration of a chronic liver disease with severe jaundice and hepatic encephalopathy. There are no cost-of-illness studies of the treatment of ACLF available. OBJECTIVES: To determine the average cost of the treatment of ACLF and testing of important clinical variables for their predictive value for the treatment costs. Methodology: Based on the sample of all ACLF-patients treated in a large German university hospital from 1999 to 2001 detailed cost of the initial hospital stay and a three year follow-up period were determined. Data on resource use were collected from hospitals patient files and internal statistics as well as by standardized interviews and questionnaires to patients and their treating GPs. Costs were calculated from a German health care system perspective and standardized to EUR of 2002. Additionally to age, sex, aetiology and severity of liver failure another 15 relevant clinical variables were tested in single and multiple regression analyses. RESULTS: A total of 69 patients with ACLF could be identified. Mean costs per patient were €21,058, €11,259 for the initial hospital stay and £9799 for the following 3 years. Biggest influence had treatment with artificial liver support systems. Other significant variables in the model were renal dialysis and aetiology of the disease. All other variables including sex, age, severity of ACLF and several laboratory parameter did not have a relevant influence on the costs. CONCLUSION: A straight and relatively simple method to identify the main cost drivers for ACLF-treatment is presented. The results are absolutely plausible from a clinical point of view and stable to variation of the model structure. The results underline the necessity to differentiate the reimbursement systems for hepatorenal syndrome or additional renal failure, artificial liver support and the aetiology of ACLF.

THE IMPACT OF GASTROESOPHAGEAL REFLUX DISEASE ON WORK PRODUCTIVITY: A SYSTEMATIC REVIEW

Wahlqvist P1, Reilly M1, Barkun A1
1AstraZeneca, Mölndal, Sweden; 2Margaret Reilly Associates, Inc, New York, NY, USA; 3McGill University Health Centre, Montreal, QC, Canada

OBJECTIVES: Gastroesophageal reflux disease (GERD) is a chronic, potentially debilitating condition characterized by frequent and persistent heartburn and acid regurgitation. The objective of this study was to evaluate the effects of GERD on work productivity, defined as productivity loss due to absenteeism and reduced effectiveness while working (presenteeism).

METHODS: Studies quantifying health-related work productivity loss in individuals with GERD were identified using systematic literature searches. Work productivity loss due to absenteeism was expressed as number of hours lost, and as the percentage of the total employed time. Presenteeism was expressed as number of hours lost, and as the percentage reduced effectiveness while at work. Overall productivity losses (absenteeism plus presenteeism) were valued in US dollars using the human capital method. RESULTS: Six publications covering five studies conducted in the USA, Canada and Sweden were eligible for inclusion. Reported work productivity losses among individuals with GERD ranged from 6% to 40%, and were primarily due to presenteeism (6%–40%) rather than absenteeism (<1%–6%). Work productivity impairment correlated with symptom severity, and was greatest in patients experiencing sleep disturbance due to GERD symptoms and lowest in GERD patients taking prescription medication. Acid-suppressive therapy improved productivity at work, especially in individuals with GERD-associated sleep disturbances. The mean overall productivity losses per employee with GERD were estimated at $51–$396 per week, assuming a 40-hour working week and average US wages. CONCLUSION: GERD has a substantial economic impact, primarily by impairing employee productivity while at work. The burden of lost productivity may be reduced by acid-suppressive therapy, especially in employees with nighttime symptoms of GERD.

WORK ABSENTEEISM IN IRRITABLE BOWEL SYNDROME (IBS): MEASURING DAYS VS HOURS MISSED

Reilly M1, McBurney C2, Bracco A1
1Margaret Reilly Associates, Inc, New York, NY, USA; 2Novartis Pharma AG, Basel, Switzerland

OBJECTIVES: To compare the accuracy of two absenteeism measures (days missed and hours missed) for inclusion in economic evaluations of IBS. METHODS: 135 IBS patients recruited from five US gastroenterology practices completed the Work Productivity and Activity Impairment questionnaire for IBS (WPAI:IBS), which assesses absenteeism with hours missed, and also completed questions about days and partial days missed. Days and partial days were considered to be the equivalent of 8 hours and 4 hours, respectively. RESULTS: 125 patients were employed, had complete data, and were included in the analysis. A total of 6.4% of patients reported missing days from work due to IBS in the prior 7 days, with an overall absenteeism rate of 1.8%; 28.0% of patients reported missing hours, with an overall absenteeism rate of 4.3%. Among those reporting hours missed, 42.9% missed less than 3 hours, 34.3% missed 3 to 5 hours, and 22.9% missed 8 to 30 hours. When days missed was used to measure absenteeism, 77.2% of patients missing hours and 60.7% of time missed due to IBS were not counted; when hours missed was reported, all patients reporting days missed were counted. Combining partial days missed with days missed increased the correspondence between those reporting days and hours missed, but considerably overestimated absenteeism because partial-day absences were often less than 4 hours. Previous validation of the WPAI:IBS hours missed measure of absenteeism relative to measures of disease severity, verbatim responses and retrospective diaries, corroborates the inaccuracy of the days missed measure. CONCLUSIONS: Hours missed from work, not days missed, is a more accurate measure for capturing the partial-day absences characteristic of IBS patients. Other chronic disorders like IBS may exhibit a similar pattern of widespread absences of short duration, and that absenteeism may go undetected when days missed is the measure of absenteeism.

MEDICAL RESOURCE USE AND DIRECT MEDICAL COST OF CHRONIC HEPATITIS C VIRUS INFECTION (HCVI) IN BRAZIL

Fonseca MC, Araujo GTB
AxiaBio Consulting, São Paulo, Brazil

OBJECTIVES: In Brazil it is estimated that there are more than 3 million patients chronically infected with HCV, making this disease a major public health problem. HCVI leads to chronic liver disease states such as cirrhosis and the need for transplantation. There is little published data on the cost of HCVI in Brazil. The aim of this study is to investigate medical resource use and direct treatment costs for each state of HCV infection from the perspective of the private medicine payers in Brazil.

METHODS: Three Delphi panels were performed, one with hepatologists, one with intensivists and another with oncologists in order to delineate practice patterns and to obtain resource utilization for routine treatment and monitoring, adverse event management and other clinical parameters representative...